An interventional study of Psychosocial Skills Training (RUTBE) in Psychotic Disorders, Self-stigma and Forgiveness, sponsored by Ömer USLU. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Ömer USLU · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Psychotic Disorders with a site in Turkey — 5 open to participants now, 6 under way, 1 of them phase 3. Psychotic Disorders · Turkey.
Among the 19 studies in Psychotic Disorders with a site in Turkey, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is one of 6 that started in 2026, is one of 9 with no phase, and was the 19th registered.
1,591 studies on the registry are indexed under Psychotic Disorders; 282 are open to participants now.
Browse Psychotic Disorders studies →5 of the 19 studies in Psychotic Disorders with a site in Turkey are open now. Recruiting first, the newest first:
Philipp Homan · Sites in Turkey, Czechia, Ireland and 3 more countries
Ages 18–65 · Healthy volunteers
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Turkey, United States, Argentina and 22 more countries
Ages 55–90
Dokuz Eylul University · Sites in Turkey
Ages 18–65
Biruni University · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 205 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 143 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 34 is below the median of 65 across 1,324 interventional studies indexed under Psychotic Disorders.
Median enrollment 50 across the 13 interventional studies, 111 across the 6 observational. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 19 have an industry lead sponsor. The 10 most frequent:
Ömer USLU is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Ömer USLU has 2 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies in Psychotic Disorders with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT07879118Biruni UniversityEffect of Occupational Therapy on Psychosocial Parameters and Functioning in Individuals With Severe Mental Illness | 2026-12 |
| NCT07898852Dokuz Eylul UniversityIntegrated Psychoeducation Program for Internalized Stigma in Schizophrenia | 2026-12-25 |
| NCT07948850Ömer USLUEffects of Psychosocial Skills Training on Self-Stigma and Forgiveness Among Caregivers of Individuals With Psychotic Disorders | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Psychotic Disorders with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial aims to evaluate the effects of psychosocial skills training on self-stigma and forgiveness among family caregivers of individuals with psychotic disorders. Caring for a person with a long-term mental illness can create emotional and social challenges. Family caregivers may experience stigma, difficulties in social relationships, and challenges related to forgiveness.
The study will include 34 adult caregivers who will be randomly assigned to an intervention group (n=17) or a control group (n=17). The intervention group will receive an eight-session, face-to-face psychosocial skills training program delivered once a week. The program will focus on understanding mental illness, improving communication and problem-solving skills, supporting treatment, managing persistent symptoms, coping with stress, and strengthening social functioning. The control group will not receive the training during the study period.
Self-stigma and forgiveness will be assessed in both groups before the intervention, immediately after the eight-session program, and three months after the intervention. The findings will help determine whether psychosocial skills training can reduce self-stigma and improve forgiveness among caregivers of individuals with psychotic disorders.
This study is designed as a two-arm, parallel-group randomized controlled trial to investigate the effects of psychosocial skills training on self-stigma and forgiveness among caregivers of individuals diagnosed with psychotic disorders. The study will be conducted at the Community Mental Health Center affiliated with Söke Fehime Faik Kocagöz State Hospital in Aydın, Türkiye.
A total of 34 caregivers will be recruited and randomly allocated to an intervention group (n=17) or a control group (n=17) using randomizer.org. Eligible participants will be adults aged 18 years or older who are literate and provide care to an individual diagnosed with a psychotic or schizophrenia spectrum disorder according to DSM-5 criteria. Caregivers whose conditions substantially interfere with effective communication will not be eligible. Participation will be voluntary, and informed consent will be obtained before data collection.
The intervention group will participate in a structured psychosocial skills training program based on the principles of Liberman's Social and Independent Living Skills Program and the training manual developed by Yıldız. The program will consist of eight weekly, face-to-face group sessions lasting approximately 90-120 minutes each. The sessions will address group preparation and communication, understanding mental illness and daily living skills, cognitive and perceptual disturbances, treatment and medication management, coping with persistent symptoms and early warning signs, avoiding harmful or ineffective treatments, stress management and self-confidence, and social functioning. Interactive discussions, practical exercises, and homework assignments will be used to support learning and application of skills. Homework reminders may be provided by telephone calls or messages.
The control group will not receive the structured psychosocial skills training during the intervention and follow-up periods. Following completion of the three-month follow-up assessment, the training will also be offered to the control group.
Data will be collected at three time points: baseline, immediately after completion of the eight-session intervention, and three months after the intervention. The Self-Stigma Scale-Family Form will be used to assess caregivers' self-stigma, and the Forgiveness Scale will be used to assess forgiveness. A personal information form will be administered at baseline to collect sociodemographic characteristics.
The study will compare changes in self-stigma and forgiveness scores between the intervention and control groups over time. The findings are expected to provide evidence regarding the potential benefits of structured psychosocial skills training for caregivers of individuals with psychotic disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive an eight-session, face-to-face psychosocial skills training program delivered once weekly. Each session will last approximately 90-120 minutes.
Behavioral: Psychosocial Skills Training (RUTBE)
Participants in this group will not receive the structured psychosocial skills training program during the intervention and follow-up periods. The training will be offered after completion of the three-month follow-up assessment.
The intervention consists of eight weekly, face-to-face psychosocial skills training sessions for family caregivers of individuals with psychotic disorders. Each session will last approximately 90-120 minutes. The program focuses on mental illness awareness, communication, problem-solving, treatment support, symptom management, stress management, and social functioning.
Change in Caregiver Self-Stigma
Caregiver self-stigma will be assessed using the Self-Stigma Scale-Family Form, a 14-item instrument rated on a five-point Likert scale. Changes in self-stigma scores will be compared between the intervention and control groups across three assessment points.
Time frame: Baseline, immediately after the 8-week intervention, and 3 months after the intervention
Change in Caregiver Forgiveness
Forgiveness will be assessed using the Forgiveness Scale, a 13-item instrument rated on a seven-point Likert scale. Changes in forgiveness scores will be compared between the intervention and control groups across three assessment points.
Time frame: Baseline, immediately after the 8-week intervention, and 3 months after the intervention
Plan to share: No — Individual participant data will not be shared with other researchers due to the sensitive nature of the psychosocial information collected from family caregivers of individuals with psychotic disorders and the need to protect participant confidentiality and privacy. Study findings will be reported in aggregate form without identifying individual participants.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
Of 459 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 5 months is below that.
Counting every sponsor, half of 461 studies reached it within 34 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ömer USLU